Information Provided By:
Fly News Breaks for July 30, 2019
Jul 30, 2019 | 07:00 EDT
Needham analyst Stephen Unger issued a double-downgrade of Genomic Health (GHDX) to Hold from Strong Buy after its decision to be acquired by Exact Sciences (EXAS) in a cash and stock deal. The analyst does not believe another buy will step in, with the transaction expected to be completed before the end of Q4.
News For GHDX;EXAS From the Last 2 Days
There are no results for your query GHDX;EXAS